Literature DB >> 8250654

Case management and plasma half-life in a case of brodifacoum poisoning.

B R Hollinger1, T P Pastoor.   

Abstract

Brodifacoum is a readily available, second-generation anticoagulant rodenticide (superwarfarin) that causes extended depletion of vitamin K1-dependent clotting factors. Brodifacoum ingestions are being reported with increasing frequency. For the first time, we compare plasma brodifacoum concentration to prothrombin levels over time in a case of brodifacoum poisoning. Brodifacoum was eliminated according to a two-compartment model, with an initial half-life of 0.75 days and a terminal half-life of 24.2 days. On admission, the brodifacoum level was 731 micrograms/L and the patient suffered severe urinary tract hemorrhage, requiring transfusion of blood products. Persistently increased prothrombin times necessitated treatment with phytonadione up to 80 mg/d for 4 months, until the brodifacoum level reached 10 micrograms/L. These data may help project the duration of phytonadione treatment required in future cases of brodifacoum poisoning. Superwarfarin exposure must be suspected in an otherwise unexplained vitamin K1-deficient coagulopathy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8250654

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  10 in total

Review 1.  The emerging threat of superwarfarins: history, detection, mechanisms, and countermeasures.

Authors:  Douglas L Feinstein; Belinda S Akpa; Manuela A Ayee; Anne I Boullerne; David Braun; Sergey V Brodsky; David Gidalevitz; Zane Hauck; Sergey Kalinin; Kathy Kowal; Ivan Kuzmenko; Kinga Lis; Natalia Marangoni; Michael W Martynowycz; Israel Rubinstein; Richard van Breemen; Kyle Ware; Guy Weinberg
Journal:  Ann N Y Acad Sci       Date:  2016-05-31       Impact factor: 5.691

2.  Brodifacoum induces early hemoglobinuria and late hematuria in rats: novel rapid biomarkers of poisoning.

Authors:  Kyle M Ware; Douglas L Feinstein; Israel Rubinstein; Guy Weinberg; Brad H Rovin; Lee Hebert; Navin Muni; Rachel E Cianciolo; Anjali A Satoskar; Tibor Nadasdy; Sergey V Brodsky
Journal:  Am J Nephrol       Date:  2015-06-20       Impact factor: 3.754

3.  Oral administration of injectable vitamin K1 in brodifacoum intoxication.

Authors:  Yen-Jung Chu; Jing-Hua Lin; Dong-Zong Hung
Journal:  Biomedicine (Taipei)       Date:  2022-06-01

4.  The Bile Sequestrant Cholestyramine Increases Survival in a Rabbit Model of Brodifacoum Poisoning.

Authors:  Matthew Lindeblad; Alexander Lyubimov; Richard van Breemen; Kamil Gierszal; Guy Weinberg; Israel Rubinstein; Douglas L Feinstein
Journal:  Toxicol Sci       Date:  2018-10-01       Impact factor: 4.849

Review 5.  Ingestion of superwarfarin leading to coagulopathy: a case report and review of the literature.

Authors:  Austin T Nelson; Joshua D Hartzell; Kenneth More; Steven J Durning
Journal:  MedGenMed       Date:  2006-11-28

6.  Treatment of a long-acting anticoagulant rodenticide poisoning cohort with vitamin K1 during the maintenance period.

Authors:  Jianhai Long; Xiaobo Peng; Yuan Luo; Yawei Sun; Guodong Lin; Yongan Wang; Zewu Qiu
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

7.  Brodifacoum does not modulate human cannabinoid receptor-mediated hyperpolarization of AtT20 cells or inhibition of adenylyl cyclase in HEK 293 cells.

Authors:  Shivani Sachdev; Rochelle Boyd; Natasha L Grimsey; Marina Santiago; Mark Connor
Journal:  PeerJ       Date:  2019-09-25       Impact factor: 2.984

Review 8.  Scaling basic toxicokinetic parameters from rat to man.

Authors:  K Bachmann; D Pardoe; D White
Journal:  Environ Health Perspect       Date:  1996-04       Impact factor: 9.031

9.  Anticoagulant rodenticide intoxication in east China: a three-year analysis.

Authors:  Hui Yan; Lin Zhu; Xianyi Zhuo; Min Shen; Ping Xiang
Journal:  Forensic Sci Res       Date:  2016-12-14

10.  Synthetic cannabinoid-associated coagulopathy secondary to long-acting anticoagulant rodenticides: Observational case series and management recommendations.

Authors:  Mona N Bahouth; Peggy Kraus; Kathryn Dane; Manuela Plazas Montana; William Tsao; Burton Tabaac; Jagar Jasem; Holly Schmidlin; Evan Einstein; Michael B Streiff; Satish Shanbhag
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.